Xenex LightStrike UV Robots Deactivate SARS-CoV-2 on Surfaces in 2 Minutes in New Peer-Reviewed Study

8-Oct-2020 4:15 PM EDT, by Xenex Disinfection Services

Newswise — The LightStrike pulsed xenon disinfection robot is the first ultraviolet (UV) room disinfection technology proven to deactivate SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2). The LightStrike robot achieved a greater than 99.99% level of disinfection against SARS-CoV-2, which is the virus that causes COVID-19, in two minutes. Testing was performed in a biosafety level 4 lab at Texas Biomedical Research Institute, one of the world’s leading independent research institutes working exclusively on infectious diseases.

The new peer-reviewed and published study, titled “Deactivation of SARS-CoV-2 with pulsed-xenon ultraviolet light: Implications for environmental COVID-19 control” is published in Infection Control and Hospital Epidemiology. The authors include highly regarded physicians and infectious disease experts from the Central Texas Veterans Healthcare System, HonorHealth, Mayo Clinic, Texas Biomedical Research Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, University of California-San Francisco, West Virginia University Medicine, and Xenex.

“Deactivating SARS-CoV-2 on surfaces is a critical and necessary step to protect people as businesses and schools begin to reopen and people return to work. Individuals with COVID-19 and asymptomatic carriers of SARS-CoV-2 contaminate their environment, and SARS-CoV-2 has been shown to be viable on surfaces for up to three days,” said Dr. Mark Stibich, Chief Scientific Officer of Xenex. “We convened a panel of some of the world’s leading infectious disease experts to validate the efficacy of pulsed xenon UV disinfection against SARS-CoV-2, and to confirm the LightStrike robot’s role as an important tool in the battle against the pandemic.”

LightStrike Germ-Zapping Robots™ use a xenon lamp to generate bursts of high intensity, broad spectrum (200-315nm) UV light. Different pathogens are susceptible to UV light at different wavelengths. With broad spectrum UV light, Xenex LightStrike robots quickly deactivate viruses, bacteria and spores at the specific wavelengths of light where the pathogens are most vulnerable without damaging materials or surfaces. More than 40 peer-reviewed studies have been published validating the efficacy of the LightStrike technology, which is now being used not only in healthcare facilities but in hotels, schools, professional sports facilities, office buildings and corporate headquarters, airports, police stations and jails, government buildings, and food processing facilities.

Prior to peer-review, Xenex’s SARS-CoV-2 efficacy results were shared in a study published on medRxiv on May 11, 2020.

About Xenex

Xenex is a world leader in UV technology-based disinfection strategies and solutions, working closely with hospitals’ infection control and EVS personnel to reduce the presence of dangerous pathogens in their facilities to provide a safer environment for patients and staff. Xenex's mission is to save lives and reduce suffering by destroying the deadly microorganisms that can cause infections. Xenex is backed by well-known investors that include EW Healthcare Partners, Piper Jaffray, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures and RK Ventures. For more information, visit xenex.com.

 

###

 

 

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5584
Released: 7-May-2021 1:40 PM EDT
There is no evidence that vaccines could cause harm to people who have recovered from COVID-19
Newswise

An article published by Robert F. Kennedy Jr.’s anti-vaccination organization and widely shared on social media questions the need of vaccinating those who’ve already recovered from COVID-19. The article says there’s a "potential risk of harm, including death" in getting the vaccines. We report this claim as false. There is no evidence that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events.

Newswise: Abbott.jpg
Released: 7-May-2021 1:00 PM EDT
FSU expert available to discuss intellectual property and COVID-19 vaccines
Florida State University

By: Bill Wellock | Published: May 7, 2021 | 11:55 am | SHARE: President Joe Biden has expressed his support for a World Trade Organization proposal to waive intellectual property rights for COVID-19 vaccines.Florida State University law professor Frederick Abbott, the Edward Ball Eminent Scholar Professor of International Law, is available to comment on international intellectual property rights and global economic issues around the proposal.

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 1:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 11:15 AM EDT
Asthma attacks plummeted among Black and hispanic/latinx individuals during the COVID-19 pandemic
Brigham and Women’s Hospital

Asthma attacks account for almost 50 percent of the cost of asthma care which totals $80 billion each year in the United States

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 9:00 AM EDT
Navigating the COVID-19 crisis to prevent pressure injuries: Learning health system helped one hospital adapt and update care in real time
Wolters Kluwer Health: Lippincott

Early in the COVID-19 pandemic, healthcare systems scrambled to modify patient care processes – particularly when it came to strategies aimed at reducing the risk of hospital-related complications. A look at how one hospital applied its learning health system (LHS) framework to respond to a COVID-19-related increase in hospital-acquired pressure injuries (HAPIs) is presented in the May/June Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Released: 7-May-2021 8:55 AM EDT
Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Texas Tech University

EviroTech LLC announced today (May 7) a $4 million investment into the company by 1701 Ventures GmbH of Göttingen, Germany, which will allow EviroTech to complete the final design, production startup and market introduction of its Ultra-Fast COVID-19 detection sensor.

Released: 7-May-2021 7:05 AM EDT
Rutgers Recruiting Participants for Pfizer COVID-19 Pediatric Vaccine Clinical Trial
Rutgers University-New Brunswick

Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children ages 6 months to 11 years. This is the third time Rutgers has served as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it conducted trials for Moderna and Johnson & Johnson.


Showing results

110 of 5584

close
1.70834